CA2056723A1 - Use of xanthines for the preparation of a medicament having immuno supressing activity - Google Patents

Use of xanthines for the preparation of a medicament having immuno supressing activity

Info

Publication number
CA2056723A1
CA2056723A1 CA002056723A CA2056723A CA2056723A1 CA 2056723 A1 CA2056723 A1 CA 2056723A1 CA 002056723 A CA002056723 A CA 002056723A CA 2056723 A CA2056723 A CA 2056723A CA 2056723 A1 CA2056723 A1 CA 2056723A1
Authority
CA
Canada
Prior art keywords
compound
group
formula
lymphocyte
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002056723A
Other languages
English (en)
French (fr)
Inventor
James A. Bianco
Jack W. Singer
William J. Novick, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Fred Hutchinson Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2056723A1 publication Critical patent/CA2056723A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002056723A 1990-11-30 1991-11-29 Use of xanthines for the preparation of a medicament having immuno supressing activity Abandoned CA2056723A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62048090A 1990-11-30 1990-11-30
US620,480 1990-11-30

Publications (1)

Publication Number Publication Date
CA2056723A1 true CA2056723A1 (en) 1992-05-31

Family

ID=24486121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002056723A Abandoned CA2056723A1 (en) 1990-11-30 1991-11-29 Use of xanthines for the preparation of a medicament having immuno supressing activity

Country Status (10)

Country Link
EP (1) EP0490181A1 (enExample)
JP (1) JPH06100450A (enExample)
KR (1) KR920009399A (enExample)
CA (1) CA2056723A1 (enExample)
HU (1) HUT59825A (enExample)
IE (1) IE914163A1 (enExample)
IL (1) IL100195A0 (enExample)
PT (1) PT99659A (enExample)
TW (1) TW205507B (enExample)
ZA (1) ZA919438B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292890B2 (en) 2012-06-29 2019-05-21 Hill-Rom Services Pte. Ltd. Wearable thorax percussion device

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021344A2 (en) * 1991-05-24 1992-12-10 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
EP0956855B1 (en) * 1998-04-24 2003-03-12 K.U. Leuven Research & Development Immunosuppressive effects of 8 substituted xanthine derivatives
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US7253176B1 (en) 2000-05-04 2007-08-07 K.U. Leuven Research & Development Immunosuppressive effects of 8-substituted xanthine derivatives
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
IN2012DN01642A (enExample) 2009-09-02 2015-06-05 Concert Pharmaceuticals Inc
EP2611807A2 (en) 2010-09-01 2013-07-10 Concert Pharmaceuticals Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0063827B1 (fr) * 1980-05-02 1985-08-14 Societe Des Produits Nestle S.A. 1-Isopropyl- et 1-isobutyl-3,7-diméthylxanthine comme médicaments
IL84934A (en) * 1986-12-31 1994-08-26 Hoechst Roussel Pharma Pharmaceutical preparations containing xanthan history to stop the activity of interleukin-1 and leukocyte-derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
GB8918297D0 (en) * 1989-08-10 1989-09-20 Beecham Group Plc Novel treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292890B2 (en) 2012-06-29 2019-05-21 Hill-Rom Services Pte. Ltd. Wearable thorax percussion device

Also Published As

Publication number Publication date
PT99659A (pt) 1992-10-30
HUT59825A (en) 1992-07-28
IE914163A1 (en) 1992-06-03
HU913721D0 (en) 1992-02-28
ZA919438B (en) 1992-08-26
IL100195A0 (en) 1992-08-18
TW205507B (enExample) 1993-05-11
EP0490181A1 (en) 1992-06-17
JPH06100450A (ja) 1994-04-12
KR920009399A (ko) 1992-06-25

Similar Documents

Publication Publication Date Title
CA2056723A1 (en) Use of xanthines for the preparation of a medicament having immuno supressing activity
Smith et al. Human lymphocyte metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin
US9284297B2 (en) Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
KR20030016376A (ko) 남성 성기능 장애의 치료
JP2015506363A (ja) ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用
EP2873417B1 (en) Immune tolerance inducer
NO178069B (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive platinakomplekser
US6420374B1 (en) Use of xanthines as immunosuppressants and to inhibit allograft reactions
US8198310B2 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
Kaye et al. Urethan carcinogenesis and nucleic acid metabolism: factors influencing lung adenoma induction
Roudebush et al. Evidence for the presence of the platelet-activating factor receptor in the CFW mouse preimplantation two-cell-stage embryo
US4180588A (en) Immunosuppressant
PT99434A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de xantina
Koch et al. Adenylate cyclase and G-proteins as a signal transfer system in the guinea pig inner ear
EP2952517A1 (en) Compound exhibiting regulatory activity on lysophosphatidylserine receptor function
US6518410B2 (en) Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments
Oka et al. Suppression of mast cell activation by GPR35: GPR35 is a primary target of disodium cromoglycate
EP0372157A1 (en) Antidiabetic phosphonates
Roy et al. In vitro inhibition of trophoblast maturation and expansion of early rat blastocysts by an oestrogen antagonist
US4962114A (en) 1-alkyl-1-sulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity
US3926949A (en) Cytokinin-3-nucleoside compounds
Fritz et al. Effects of epinephrine and insulin on glucose disappearance in eviscerated dogs
Huang Rab4acontrol over metabolism and mTOR drives disease progression in Systemic Lupus Erythematosus
Kilduff et al. Silence the alarm:(p) ppGpp reduces the expression of key innate immune system regulatory genes 3177
WO2025080995A1 (en) Pharmaceutical agent-integrin ligand conjugates for muscle delivery

Legal Events

Date Code Title Description
FZDE Discontinued